Megan A. Cooper, M.D., Ph.D.  cooper_m@wustl.edu

Profile picture
Associate Professor, Rheumatology
Rheumatology

phone: (314) 454-6124

Clinical Interests

Dr. Cooper received her MD and PhD training at The Ohio State University in Columbus, Ohio. Her PhD work focused on understanding the biology of a subset of human immune cells known as “natural killer” or NK cells. After graduating from medical school she moved to St. Louis and completed her residency and fellowship training at St. Louis Children’s Hospital and Washington University. Dr. Cooper has a clinical interest in primary disorders of the immune system and sees patients in the rheumatology and immunology clinics. She is the Director of the Clinical Immunology program and the Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies at St. Louis Children's Hospital.

Education

  • BA, The College of Wooster1995
  • PhD, The Ohio State University2002
  • MD, Cum Laude, AOA, MD/PhD Fellow, The Ohio State University2004

Training

  • Resident in Pediatrics, St. Louis Children's Hospital, Washington University2004 - 2006
  • Fellowship in Pediatric Rheumatology, Washington University2006 - 2010

Licensure and Board Certification

  • 2007 - PresAmerican Board of Pediatrics, General Pediatrics
  • 2010 - PresMO, Missouri State Medical License
  • 2011 - PresAmerican Board of Pediatrics - Pediatric Rheumatology

Honors and Awards

  • National Merit Finalist1991
  • Lewis LaShell Chemistry Scholarship, The College of Wooster1994
  • National Science Foundation Research Undergraduate Fellowship1994
  • Phi Beta Kappa National Honor Society1995
  • Bertha Bouroncle Internal Medicine Research Fellowship1998 - 1999
  • 1st Place, Oral Presentation, Landare Day Medical Student Research Forum1999
  • Howard Hughes Medical Institute (HHMI) Medical Student Research Fellow1999 - 2000
  • American Society of Hematology (ASH) Medical Student Award2001
  • Carroll L. Birch Award, for the best original research paper by a student member of the American Medical Women's Association (AMWA)2001
  • Roche Molecular Biochemicals Distinguished Graduate Seminar Award2001
  • Phi Kappa Phi National Graduate Honor Society2002
  • Alpha Omega Alpha (AOA) Honor Medical Society2003
  • Grant Morrow III, MD, Award for Excellence in Pediatrics, The Ohio State University2004
  • Internal Medicine Research Award, The Ohio State University2004
  • Medical Scientist Award, The Ohio State University College of Medicine2004
  • Watman Achievement Award, Alpha Omega Alpha Society, The Ohio State University2004
  • David Gilstrap Award, Washington University School of Medicine Department of Pediatrics2007
  • Pediatric NIH Loan Repayment Grant (LRP), NIH/NIAID2007 - 2013
  • Scholar of the NIH Child Health Research Center, Washington University Department of Pediatrics2009 - 2013
  • Best Original Basic Science Abstract, Washington University Department of Pediatrics Research Retreat2010
  • Children's Discovery Institute and St. Louis Children's Hospital Faculty Recruit Award2010 - 2015
  • Children’s Discovery Institute of Washington University and St. Louis Children’s Hospital Interdisciplinary Research Award2012 - 2015
  • The American Association of Immunologists (AAI) Early Career Faculty Travel Grant2014
  • “Lecturer of the Month”, St. Louis Children’s Hospital Residency Program, March 20162016
  • Moderator, "Advances in clinical care through whole exome sequencing", American College of Rheumatology (ACR) Annual Meeting, November 15, 2016.2016
  • Moderator, "Immunogenetic Basic Science Symposium", American Society for Histocompatibility & Immunogenetics (ASHI), September 26, 2016.2016
  • Moderator, Guided Poster Tour, 2017 Clinical Immunology Society Meeting, March 25, 2017.2017
  • Elected Member, Society for Pediatric Research (SPR)2017 - Pres
  • Emil Unanue Prize for Innovative Research in Immunology2019

Recent Publications view all (48)


  1. Multiplexed Functional Assessment of Genetic Variants in CARD11. Am J Hum Genet. 2020. PMID:33202260 
  2. Recovery from COVID-19 in a Child with Chronic Granulomatous Disease and T Cell Lymphopenia. J Clin Immunol. 2020. PMCID:PMC7588587  PMID:33108551 
  3. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515). PMID:32972996 
  4. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515). PMID:32972995 
  5. ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes. JCI Insight. 2020;5(18). PMID:32841218 
  6. Responsiveness of sphingosine phosphate lyase insufficiency syndrome to vitamin B6 cofactor supplementation. J Inherit Metab Dis. 2020;43(5):1131-1142. PMID:32233035 
  7. Siblings with a novel MED12 variant and Odho syndrome with immune defects. Clin Genet. 2020;98(3):308-310. PMID:32715471 
  8. A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection. Cell. 2020;181(6):1194-1199. PMCID:PMC7218368  PMID:32405102 
  9. Stage-Specific Requirement for Eomes in Mature NK Cell Homeostasis and Cytotoxicity. Cell Rep. 2020;31(9):107720. PMCID:PMC7265846  PMID:32492428 
  10. Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. Front Immunol. 2020;11:239. PMCID:PMC7046837  PMID:32153572 
  11. NAPDH Oxidase-Specific Flow Cytometry Allows for Rapid Genetic Triage and Classification of Novel Variants in Chronic Granulomatous Disease. J Clin Immunol. 2020;40(1):191-202. PMID:31813112 
  12. MicroRNA-142 Is Critical for the Homeostasis and Function of Type 1 Innate Lymphoid Cells. Immunity. 2019;51(3):479-490.e6. PMCID:PMC6750984  PMID:31402259 
  13. Heterozygous FOXN1 Variants Cause Low TRECs and Severe T Cell Lymphopenia, Revealing a Crucial Role of FOXN1 in Supporting Early Thymopoiesis. Am J Hum Genet. 2019;105(3):549-561. PMCID:PMC6731368  PMID:31447097 
  14. Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance. Sci Transl Med. 2019;11(495). PMCID:PMC6647037  PMID:31167928 
  15. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol. 2018;142(5):1665-1669. PMCID:PMC6322659  PMID:30092289 
  16. Identification of enhanced IFN-γ signaling in polyarticular juvenile idiopathic arthritis with mass cytometry. JCI Insight. 2018;3(15). PMCID:PMC6129135  PMID:30089725 
  17. Comment on: Evidence of innate lymphoid cell redundancy in humans. Nat Immunol. 2018;19(8):788-789. PMID:30026477 
  18. Somatic mutations and clonal hematopoiesis in congenital neutropenia. Blood. 2018;131(4):408-416. PMCID:PMC5790127  PMID:29092827 
  19. Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control. JCI Insight. 2017;2(23). PMID:29212951 
  20. Low IgE Is Insufficiently Sensitive to Guide Genetic Testing of STAT3 Gain-of-Function Mutations. Clin Chem. 2017;63(9):1539-1540. PMID:28667185 
  21. Germline hypomorphic CARD11 mutations in severe atopic disease. Nat Genet. 2017;49(8):1192-1201. PMCID:PMC5664152  PMID:28628108 
  22. Azathioprine-Associated Complete NK Cell Deficiency. J Clin Immunol. 2017;37(6):514-516. PMID:28639167 
  23. Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency. J Clin Invest. 2017;127(3):912-928. PMCID:PMC5330730  PMID:28165339 
  24. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8(357):357ra123. PMCID:PMC5436500  PMID:27655849 
  25. Mesenteric vasculitis in children with systemic lupus erythematosus. Clin Rheumatol. 2016;35(3):785-93. doi:10.1007/s10067-015-2892-3  PMID:25687984 
  26. Activation-specific metabolic requirements for NK Cell IFN-γ production. J Immunol. 2015;194(4):1954-1962. doi:10.4049/jimmunol.1402099  PMID:25595780 
  27. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood. 2015;125(4):591-599. doi:10.1182/blood-2014-09-602763  PMID:25359994 
  28. Elevated double negative T cells in pediatric autoimmunity. J Clin Immunol. 2014;34(5):594-9. doi:10.1007/s10875-014-0038-z  PMCID:PMC4047151  PMID:24760111 
  29. L-plastin is essential for alveolar macrophage production and control of pulmonary pneumococcal infection. Infect Immun. 2014;82(5):1982-93. PMCID:PMC3993441  PMID:24595139 
  30. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol Blood Marrow Transplant. 2014;20(4):463-73. doi:10.1016/j.bbmt.2014.01.006  PMCID:PMC3959288  PMID:24434782 
  31. Hypogammaglobulinemia in pediatric systemic lupus erythematosus. Lupus. 2013;22(13):1382-7. doi:10.1177/0961203313507990  PMCID:PMC3840537  PMID:24106215 
  32. Murine NK cell intrinsic cytokine-induced memory-like responses are maintained following homeostatic proliferation. J Immunol. 2013;190(9):4754-62. doi:10.4049/jimmunol.1201742  PMCID:PMC3633638  PMID:23530145 
  33. Cytokine activation induces human memory-like NK cells. Blood. 2012;120(24):4751-60. doi:10.1182/blood-2012-04-419283  PMCID:PMC3520618  PMID:22983442 
  34. Vancomycin-induced DRESS with evidence of T-cell activation in a 22-month-old patient. Ann Allergy Asthma Immunol. 2012;109(4):280-1. doi:10.1016/j.anai.2012.07.016  PMID:23010236 
  35. Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A. 2009;106(6):1915-9. doi:10.1073/pnas.0813192106  PMCID:PMC2644138  PMID:19181844 
  36. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum. 2007;56(9):3107-11. doi:10.1002/art.22856  PMID:17763414 
  37. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 2003;101(8):3052-7. doi:10.1182/blood-2002-09-2876  PMID:12480696 
  38. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood. 2002;100(10):3633-8. doi:10.1182/blood-2001-12-0293  PMID:12393617 
  39. Effects of antibody concentration on the separation of human natural killer cells in a commercial immunomagnetic separation system. Cytometry. 2001;45(4):285-93. PMID:11746098 
  40. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633-40. PMID:11698225 
  41. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 2001;97(10):3146-51. PMID:11342442 
  42. Interleukin-1beta costimulates interferon-gamma production by human natural killer cells. Eur J Immunol. 2001;31(3):792-801. PMID:11241284 
  43. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med. 2001;193(2):219-31. PMCID:PMC2193336  PMID:11208862 
  44. Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-gamma production and STAT-mediated signal transduction. Blood. 2000;96(4):1465-73. PMID:10942393 
  45. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J Clin Invest. 2000;106(1):117-24. doi:10.1172/JCI6218  PMCID:PMC314354  PMID:10880055 
  46. Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo. J Immunol. 2000;164(4):1643-7. PMID:10657604 
  47. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol. 1999;162(8):4511-20. PMID:10201989 
  48. Intramolecular energy transfer to trans-stilbene J Phys Chem A. 1998;102:5577-5584. 
Last updated: 11/18/2020
© 2020 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130